Skip to main content

Published locations for CTAD: Anti-tau vaccine demonstrated safety, immunogenicity in phase I study

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. CTAD: Anti-tau vaccine demonstrated safety, immunogenicity in phase I study

User login

  • Reset your password
  • /content/ctad-anti-tau-vaccine-demonstrated-safety-immunogenicity-phase-i-study
  • /familypracticenews/article/104814/alzheimers-cognition/ctad-anti-tau-vaccine-demonstrated-safety
  • /internalmedicinenews/article/104814/alzheimers-cognition/ctad-anti-tau-vaccine-demonstrated-safety
  • /psychiatry/article/104814/alzheimers-cognition/ctad-anti-tau-vaccine-demonstrated-safety
  • /internalmedicine/article/104814/alzheimers-cognition/ctad-anti-tau-vaccine-demonstrated-safety
  • /neurology/article/104814/alzheimers-cognition/ctad-anti-tau-vaccine-demonstrated-safety
  • /familymedicine/article/104814/alzheimers-cognition/ctad-anti-tau-vaccine-demonstrated-safety
  • /clinicalneurologynews/article/104814/alzheimers-cognition/ctad-anti-tau-vaccine-demonstrated-safety
  • /clinicalpsychiatrynews/article/104814/alzheimers-cognition/ctad-anti-tau-vaccine-demonstrated-safety